Clinical Trial Update: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether CD34+ cell dose influences absolute lymphocyte count after high-dose therapy and autologous stem cell transplantation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING